The Microbiome as a Therapeutic Target in Inflammatory Arthritis

The bacteria living in the gut of people with inflammatory arthritis are different from those in healthy individuals, and this consortium aims to find out whether those microbial changes actually cause joint inflammation or are merely a consequence of the disease. Current treatments for rheumatoid arthritis and spondyloarthritis often fail or lose effectiveness over time, partly because doctors do not fully understand what drives the disease. The link between gut bacteria and the immune system is a promising but poorly understood piece of that puzzle. This project brings together microbiologists, immunologists, and computational biologists to sequence the gut microbes of arthritis patients, grow those bacteria in the lab, and test how they interact with human immune cells. If the consortium succeeds in proving that specific gut bacteria drive joint inflammation, the practical payoff could be substantial. Doctors might one day use a stool sample to predict which patients will develop severe arthritis, or to choose the most effective drug for each person. More ambitiously, it could open the door to treatments that target the gut directly—such as probiotics, dietary changes, or drugs that block bacterial signals—rather than suppressing the entire immune system. This is still fundamental science, but it lays the groundwork for a shift from managing symptoms to addressing an underlying cause.